StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
33
Publishing Date
2021 - 12 - 13
33
Sector
Health technology
29
Manufacturing
2
Professional, scientific, and technical services
1
Tags
Acquisition
16
Acquisition corp
5
Alliances
5
Als
24
Approval
4
Authorization
4
Biopharma
5
Bioscience
5
Biotech
8
Biotech-bay
5
Cancer
10
Car-t
6
Clinical-trials-phase-ii
14
Collaboration
6
Conference
8
Contract
6
Covid
6
Covid-19
6
Drug
5
Ema
27
Energy
11
Europe
10
Events
8
Fda
5
Genetown
5
Grant
6
Granted
7
Growth
6
Health
10
Index
9
Iot
13
Ipo
5
Liver
6
N/a
282
Nasdaq
11
Offering
9
Partnership
9
People
11
Pharm-country
6
Phase 1
13
Phase 2
10
Phase 2b
5
Phase 3
7
Platform
9
Positive
19
Potential
6
Pre-clinical
10
Preclinical
10
Presentation
8
Research
24
Response
5
Results
19
T-cell
10
Technology
14
Test
10
Therapeutics
33
Therapy
12
Treatment
15
Trial
28
Trials
5
Entities
Allogene therapeutics, inc.
2
Aprea therapeutics, inc.
1
Aquestive therapeutics, inc.
1
Arch therapeutics, inc.
1
Arcturus therapeutics holdings inc.
1
Autolus therapeutics plc
1
Avenue therapeutics, inc.
1
Biomx inc.
1
Brainstorm cell therapeutics inc.
1
Capricor therapeutics, inc.
1
Diamedica therapeutics inc.
1
Eli lilly and company
2
Fate therapeutics, inc.
2
Galectin therapeutics inc.
1
Geron corporation
1
Harpoon therapeutics, inc.
1
Incyte corporation
1
Intellia therapeutics, inc.
1
Iterum therapeutics plc
1
Johnson & johnson
1
Keros therapeutics, inc.
3
Krystal biotech, inc.
1
Kymera therapeutics, inc.
1
Nektar therapeutics
1
Onconova therapeutics, inc.
1
Oncternal therapeutics, inc.
1
Poseida therapeutics, inc.
1
Sensei biotherapeutics inc
1
Sigilon therapeutics inc
1
Stealth biotherapeutics corp.
1
Takeda pharmaceutical company limited
1
Tg therapeutics, inc.
1
Tscan therapeutics inc
1
Viracta therapeutics inc
1
Symbols
ALLO
2
APRE
1
AQST
1
ARCT
1
ARTH
1
ATXI
1
AUTL
1
BCLI
1
CAPR
1
DMAC
1
FATE
2
GALT
1
GERN
1
HARP
1
INCY
1
ITRM
1
JNJ
1
KROS
3
KRYS
1
KYMR
1
LLY
2
MITO
1
NKTR
1
NTLA
1
ONCT
1
ONTX
1
PHGE
1
PSTX
1
SGTX
1
SNSE
1
TAK
1
TCRX
1
TGTX
1
VIRX
1
Exchanges
Amex
1
Nasdaq
33
Nyse
3
Crawled Date
2024 - 04 - 24
28
2024 - 04 - 09
27
2024 - 03 - 18
27
2024 - 03 - 05
34
2024 - 02 - 28
30
2024 - 01 - 08
36
2024 - 01 - 04
37
2024 - 01 - 03
30
2024 - 01 - 02
32
2023 - 11 - 13
35
2023 - 11 - 09
47
2023 - 11 - 07
37
2023 - 11 - 06
27
2023 - 11 - 02
37
2023 - 11 - 01
40
2023 - 10 - 31
28
2023 - 10 - 04
27
2023 - 09 - 07
28
2023 - 09 - 06
38
2023 - 09 - 05
49
2023 - 08 - 14
32
2023 - 08 - 10
26
2023 - 08 - 08
27
2023 - 08 - 03
37
2023 - 08 - 02
25
2023 - 08 - 01
25
2023 - 06 - 01
42
2023 - 05 - 31
25
2023 - 05 - 15
30
2023 - 05 - 11
43
2023 - 05 - 10
28
2023 - 05 - 09
30
2023 - 05 - 08
25
2023 - 05 - 04
33
2023 - 05 - 03
26
2023 - 05 - 02
31
2023 - 05 - 01
61
2023 - 04 - 27
30
2023 - 03 - 28
26
2023 - 03 - 15
28
2023 - 03 - 09
25
2023 - 03 - 07
28
2023 - 03 - 06
27
2023 - 03 - 01
39
2023 - 02 - 28
27
2023 - 01 - 09
26
2023 - 01 - 04
25
2022 - 12 - 01
26
2022 - 11 - 14
29
2022 - 11 - 03
33
2022 - 10 - 27
25
2022 - 10 - 26
30
2022 - 09 - 06
27
2022 - 03 - 10
26
2022 - 03 - 08
25
2022 - 03 - 02
26
2022 - 03 - 01
40
2022 - 01 - 06
26
2022 - 01 - 04
31
2021 - 12 - 13
33
Crawled Time
02:00
1
06:00
1
13:00
1
13:30
4
14:00
4
14:30
5
15:00
3
15:30
1
16:00
1
18:00
2
20:00
3
21:00
5
22:00
1
23:00
1
Source
www.biospace.com
25
www.globenewswire.com
7
www.prnewswire.com
1
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Therapeutics
crawled date :
2021 - 12 - 13
save search
Sigilon Therapeutics Announces Strategic Reprioritization
Published:
2021-12-13
(Crawled : 23:00)
- globenewswire.com
SGTX
|
$22.47
-2.56%
0.0%
0
|
Health Technology
|
718.51%
|
O:
0.0%
H:
3.56%
C:
-7.83%
therapeutics
Fate Therapeutics Showcases Positive Interim Phase 1 Data from FT596 Off-the-shelf, iPSC-derived CAR NK Cell Program for Relapsed / Refractory B-cell Lymphoma at 2021 ASH Annual Meeting
Published:
2021-12-13
(Crawled : 22:00)
- biospace.com/
FATE
|
News
|
$4.3
-5.29%
-5.58%
2M
|
Health Technology
|
-90.76%
|
O:
-0.1%
H:
0.0%
C:
0.0%
ft596
therapeutics
phase 1
positive
t-cell
Harpoon Therapeutics Provides Pipeline Update for TriTAC® Clinical Programs and T Cell Engager Platforms
Published:
2021-12-13
(Crawled : 21:00)
- globenewswire.com
HARP
|
$23.01
0.07%
6.6M
|
Health Technology
|
288.34%
|
O:
3.04%
H:
5.74%
C:
3.61%
tritac
therapeutics
platform
t-cell
Corrected: Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 63rd American Society of Hematology Annual Meeting and Exposition
Published:
2021-12-13
(Crawled : 21:00)
- globenewswire.com
KROS
|
$56.135
1.71%
1.68%
260K
|
Health Technology
|
4.43%
|
O:
-9.67%
H:
1.03%
C:
0.73%
ker-050
ema
trial
therapeutics
preclinical
results
pre-clinical
Aquestive Therapeutics Receives Written Response to Pre-IND Submission for AQST-109 (epinephrine prodrug sublingual film) and Begins Recruitment for its Epinephrine Film Pharmacokinetic and Safety Trial (EPIPHAST)
Published:
2021-12-13
(Crawled : 21:00)
- globenewswire.com
AQST
|
$3.905
-8.76%
-9.6%
2.1M
|
Health Technology
|
-18.63%
|
O:
-3.23%
H:
0.0%
C:
0.0%
aqst-109
drug
trial
therapeutics
epinephrine
submission
Galectin Therapeutics Discusses Corporate Transformation, Progress of NAVIGATE Trial and Outlines Strategy for Potential Phase 2 Cancer Immunotherapy Trial at Annual Meeting
Published:
2021-12-13
(Crawled : 21:00)
- globenewswire.com
GALT
|
$3.29
-2.66%
-2.74%
160K
|
Health Technology
|
50.89%
|
O:
-0.67%
H:
0.0%
C:
0.0%
phase 2
trial
therapeutics
immunotherapy
potential
therapy
cancer
Sensei Biotherapeutics Announces Addition to the Nasdaq Biotechnology Index
Published:
2021-12-13
(Crawled : 21:00)
- globenewswire.com
SNSE
|
$0.96
-3.78%
-3.93%
55K
|
|
-82.27%
|
O:
4.61%
H:
0.0%
C:
-6.78%
technology
therapeutics
index
biotech
iot
nasdaq
Allogene Therapeutics Reports Positive Results from Phase 1 UNIVERSAL Study of Single Dose ALLO-715 AlloCAR T™ Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 63rd American Society of Hematology Annual Meeting
Published:
2021-12-13
(Crawled : 20:00)
- biospace.com/
ALLO
|
$3.04
-9.79%
-10.86%
2.1M
|
Health Technology
|
-81.31%
|
O:
1.05%
H:
2.52%
C:
-22.56%
allo-715
ema
therapeutics
positive results
phase 1
positive
therapy
results
t-cell
Allogene Therapeutics Reports Positive Phase 1 Data from the ALPHA Trials in Non-Hodgkin’s Lymphoma at the 63rd Annual Meeting of the American Society of Hematology
Published:
2021-12-13
(Crawled : 20:00)
- biospace.com/
ALLO
|
$3.04
-9.79%
-10.86%
2.1M
|
Health Technology
|
-81.31%
|
O:
1.05%
H:
2.52%
C:
-22.56%
ema
als
trials
trial
therapeutics
phase 1
positive
Viracta Therapeutics Announces Final Phase 1b/2 Data Showing Promising and Durable Signal of Efficacy for Nana-val in Relapsed/Refractory Epstein-Barr Virus-Positive Lymphoma in an Oral Presentation at ASH 2021
Published:
2021-12-13
(Crawled : 20:00)
- biospace.com/
VIRX
|
$0.8367
-1.31%
-1.33%
55K
|
Manufacturing
|
-79.76%
|
O:
-2.86%
H:
0.0%
C:
0.0%
phase 1b
therapeutics
presentation
phase 1
positive
phase 2b
Neurona Therapeutics Announces C-Suite Leadership Team
Published:
2021-12-13
(Crawled : 18:00)
- biospace.com/
GERN
|
$3.57
2.0%
1.96%
6.6M
|
Health Technology
|
167.18%
|
O:
-0.76%
H:
0.0%
C:
0.0%
therapeutics
Autolus Therapeutics presents positive obe-cel data at the 63rd ASH Annual Meeting & Exposition
Published:
2021-12-13
(Crawled : 18:00)
- biospace.com/
AUTL
|
$4.23
-5.58%
-5.91%
2.7M
|
Health Technology
|
-34.79%
|
O:
-3.93%
H:
0.0%
C:
0.0%
therapeutics
positive
cel
Poseida Therapeutics Provides Update on BCMA-Targeted CAR-T Clinical Trials at the 2021 American Society of Hematology (ASH) Annual Meeting
Published:
2021-12-13
(Crawled : 16:00)
- biospace.com/
PSTX
|
$2.065
-4.4%
-4.6%
350K
|
Health Technology
|
-69.58%
|
O:
0.28%
H:
0.0%
C:
0.0%
ema
als
car-t
trials
trial
therapeutics
clinical trials
TScan Therapeutics Announces Poster Presentations at the 63rd American Society of Hematology Annual Meeting and Exposition
Published:
2021-12-13
(Crawled : 15:30)
- biospace.com/
TCRX
|
News
3 d
|
$7.39
1.79%
1.76%
91K
|
Professional, Scientific, and T...
|
18.63%
|
O:
0.0%
H:
0.0%
C:
0.0%
ema
therapeutics
presentation
scan
Fate Therapeutics Highlights Positive Durability of Response Data from FT516 Phase 1 Study for B-cell Lymphoma and Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to FT516 for Relapsed / Refractory DLBCL
Published:
2021-12-13
(Crawled : 15:00)
- biospace.com/
FATE
|
News
|
$4.3
-5.29%
-5.58%
2M
|
Health Technology
|
-90.76%
|
O:
-0.1%
H:
0.0%
C:
0.0%
ft516
fda
granted
therapeutics
phase 1
positive
therapy
t-cell
designation
DiaMedica Therapeutics Announces Participation in LifeSci Partners 11th Annual Corporate Access Event
Published:
2021-12-13
(Crawled : 15:00)
- biospace.com/
DMAC
|
$2.5
3.31%
3.2%
7.4K
|
Health Technology
|
-36.65%
|
O:
0.26%
H:
0.0%
C:
0.0%
therapeutics
Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its KER-050 Program and Preclinical Data from its ALK2 Inhibitor Program at the 63rd American Society of Hematology Annual Meeting and Exposition
Published:
2021-12-13
(Crawled : 15:00)
- biospace.com/
KROS
|
$56.135
1.71%
1.68%
260K
|
Health Technology
|
0.6%
|
O:
-3.66%
H:
0.0%
C:
0.0%
ker-050
ema
trial
therapeutics
preclinical
results
pre-clinical
Nektar Therapeutics Presents Clinical Data for NKTR-255 in Patients with Relapsed/Refractory Hematologic Malignancies, Including Patients with Prior CAR-T Therapy, at the 63rd American Society of Hematology (ASH) Annual Meeting
Published:
2021-12-13
(Crawled : 14:30)
- biospace.com/
LLY
|
News
|
$732.2
-1.81%
0.18%
2.1M
|
Health Technology
|
204.6%
|
O:
1.27%
H:
0.0%
C:
0.0%
NKTR
|
News
|
$1.39
-2.11%
-2.16%
960K
|
Health Technology
|
-89.01%
|
O:
-3.33%
H:
0.0%
C:
0.0%
nktr-255
ema
car-t
therapeutics
therapy
Capricor Therapeutics Announces Key Updates on its Vaccine and Therapeutic Programs for COVID-19
Published:
2021-12-13
(Crawled : 14:30)
- biospace.com/
CAPR
|
$5.04
4.56%
4.37%
910K
|
Health Technology
|
54.49%
|
O:
-1.92%
H:
0.0%
C:
0.0%
covid-19
therapeutics
covid
vaccine
Intellia Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema
Published:
2021-12-13
(Crawled : 14:30)
- biospace.com/
NTLA
|
$21.16
-1.72%
-1.75%
860K
|
Health Technology
|
-81.12%
|
O:
1.12%
H:
0.0%
C:
0.0%
ntla-2002
treatment
ema
trial
therapeutics
intel
phase 1
hereditary angioedema
← Previous
1
2
Next →
Gainers vs Losers
62%
38%
Top 10 Gainers
CSSE
4
|
$0.4323
183.85%
64.77%
220M
|
Consumer Services
BOF
|
$1.99
70.09%
41.21%
110M
|
ILAG
|
$0.51
6.03%
40.62%
1.7M
|
LICN
|
$0.941
68.04%
40.49%
15M
|
AMST
|
$3.31
65.5%
39.58%
70M
|
Technology Services
MTC
|
$3.615
61.38%
38.04%
9.3M
|
Technology Services
WIMI
|
$1.15
58.53%
36.92%
19M
|
Technology Services
AIH
|
$0.45
12.5%
30.92%
320K
|
Health Services
MULN
|
News
|
$3.78
38.46%
27.78%
13M
|
Information
RILY
|
$29.86
37.48%
27.26%
12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.